The objective of this study was to confirm if two formulations of cephalexin suspension are
bioequivalent.
Test product was Ceporex® (250 mg Cephalexin / 5 ml; GlaxoSmithKline) and reference product
Keflex® (125 mg Cephalexin / 5 ml; Eli Lilly). The single dosage was 10 ml of suspension for
Ceporex and 20 ml of suspension for Keflex® .
The study was prospective, open-label, randomized, crossover, single dose, with 02
treatments, 02 sequences and 02 periods, under fasting conditions.
The population was composed of 28 healthy volunteers, both genders, adults between 18-50
years.
The comparative bioavailability of the two formulations was evaluated based in statistical
comparisons of relevant pharmacokinetic parameters, obtained from data of drug concentrations
in blood.